Background: Intentional weight loss with bariatric surgery is associated with better outcomes in younger patients with prevalent HF. However, temporal trends in use of bariatric surgery and anti-obesity medications (AOM) among older patients with new onset HF and obesity, and their effect on CV outcomes are not well studied. Methods: Medicare patients with obesity and new onset HF from 2013 to 2019 were identified using the 100% inpatient files. Patients who underwent bariatric surgery were matched to controls in a 1:2 ratio (matched on age, sex, race, BMI, and HF diagnosis year, and comorbidities). In a random 5% sample with available Part D data, HF patients with obesity who were prescribed AOM (Semaglutide, liraglutide, naltrexone or orlistat) were identified and matched to HF controls as above. Cox models were used to evaluate the association of weight loss therapies (modeled as a time-varying dependent variable) and risk of mortality, atrial fibrillation (AF), and HF readmission rate. Results: Overall, 1.5% (2684 of 174,196) patients with new onset HF and BMI ≥35 underwent bariatric surgery (46% men, age 55 y and BMI 52 Kg/m2). Bariatric surgery use increased from 0.3% in 2013 to 1.4% in 2019 (P <0.01). In propensity-matched analyses (surgery N=2144 vs. control N=3920, f/u of 4.2 y), bariatric surgery following incident HF was associated with a significantly lower risk of mortality and new-onset AF (Figure), and a lower rate of HF readmissions (pre- vs. post-surgery rate: 0.9 vs. 0.3/100 person-days). In the subset with Part D data (N=36603), use of AOM was low (3.7%). In propensity-matched analysis, (AOM N=611 vs. controls N=891, f/u of 1.8 y), use of AOM were associated with 30% lower risk of mortality and 35% lower risk of AF compared with controls. Conclusions: Bariatric surgery and AOM are associated with favorable CV outcomes among HF patients with obesity. However, their utilization remains extremely low highlighting an important gap in care of HF patients with obesity.